As of the most recent data, GALT shows a ROE of 20.35%. That is below the Healthcare sector average of 20.86%. Scroll down for historical charts and peer comparison views.

The Healthcare sector average ROE is about 20.86%. Galectin Therapeutics is at 20.35%, which is lower that average. That is roughly 2.5% below the sector mean. Use the comparison chart on this page to see how GALT stacks up against individual peers as well.

Check the historical chart to see whether GALT's ROE is trending up or down. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Galectin Therapeutics with peers to see if the move is company-specific or sector-wide.

Besides this return on equity page, Stockcircle has Galectin Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect ROE (currently 20.35%) with ownership activity and broader fundamentals.

The Healthcare average ROE is about 20.86%, while GALT is at 20.35%. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.